![]()
|
|
||||||||
J. Biol. Chem., Vol. 279, Issue 38, 39671-39676, September 17, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



||
¶
||
||
||**
From the
Department of Neurogenetics, CNS Infection and Immunity Group, Faculty of Medicine, Imperial College, London W2 1PG, United Kingdom,
Unité de Virologie et Immunologie Moléculaires, Institut National de la Recherche Agronomique, 78 352 Jouy en Josas, France, and ||Medical Research Council, Prion Unit and Department of Neurodegenerative Disease, Institute of Neurology, Queen Square, London WC1N 3BG, United Kingdom
Conversion of the cellular
-helical prion protein (PrPC) into a disease-associated isoform (PrPSc) is central to the pathogenesis of prion diseases. Molecules targeting either normal or disease-associated isoforms may be of therapeutic interest, and the antibodies binding PrPC have been shown to inhibit prion accumulation in vitro. Here we investigate whether antibodies that additionally target disease-associated isoforms such as PrPSc inhibit prion replication in ovine PrP-inducible scrapie-infected Rov cells. We conclude from these experiments that antibodies exclusively binding PrPC were relatively inefficient inhibitors of ScRov cell PrPSc accumulation compared with antibodies that additionally targeted disease-associated PrP isoforms. Although the mechanism by which these monoclonal antibodies inhibit prion replication is unclear, some of the data suggest that antibodies might actively increase PrPSc turnover. Thus antibodies that bind to both normal and disease-associated isoforms represent very promising anti-prion agents.
Received for publication, March 1, 2004 , and in revised form, May 6, 2004.
* This work was supported by grants from the Medical Research Council (London, United Kingdom) and by a Marie Curie Fellowship grant from the European Union. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ Present address: UMR754 Rétrovirus et Pathologie Comparée, Institut National de la Recherche Agronomique, 69 366 Lyon, France.
** Present address. To whom correspondence should be addressed: Brain and Mind Research Institute, University of Sydney, New South Wales 2006, Australia. Tel.: 61263620711; Fax: 61263620129; E-mail: s.hawke{at}imperial.ac.uk.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
A. Sacquin, A. S. Bergot, P. Aucouturier, and M. Bruley-Rosset Contribution of Antibody and T Cell-Specific Responses to the Progression of 139A-Scrapie in C57BL/6 Mice Immunized with Prion Protein Peptides J. Immunol., July 1, 2008; 181(1): 768 - 775. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R Trevitt and J. Collinge A systematic review of prion therapeutics in experimental models Brain, September 1, 2006; 129(9): 2241 - 2265. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gregoire, A. S. Bergot, C. Feraudet, C. Carnaud, P. Aucouturier, and M. B. Rosset The Murine B Cell Repertoire Is Severely Selected against Endogenous Cellular Prion Protein J. Immunol., November 15, 2005; 175(10): 6443 - 6449. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Feraudet, N. Morel, S. Simon, H. Volland, Y. Frobert, C. Creminon, D. Vilette, S. Lehmann, and J. Grassi Screening of 145 Anti-PrP Monoclonal Antibodies for Their Capacity to Inhibit PrPSc Replication in Infected Cells J. Biol. Chem., March 25, 2005; 280(12): 11247 - 11258. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |